181 related articles for article (PubMed ID: 531060)
1. Chelation therapy and ferritin levels in patients with homozygous beta-thalassemia.
Kattamis C; Lagos P; Langona E
Prog Clin Biol Res; 1979; 34():351-9. PubMed ID: 531060
[No Abstract] [Full Text] [Related]
2. [Chelating therapy in beta-thalassemia].
Musumeci S; Romeo MA; Di Gregorio F; Schiliró G; Russo G
Pediatr Med Chir; 1982; 4(1-2):55-9. PubMed ID: 7111040
[TBL] [Abstract][Full Text] [Related]
3. High-dose intravenous chelation therapy with deferoxamine.
Cohen A; Mizanin J; Schwartz E
Prog Clin Biol Res; 1989; 309():125-31. PubMed ID: 2780746
[No Abstract] [Full Text] [Related]
4. [Serum ferritin in the follow-up of homozygotic beta-thalassemia treated with blood transfusion and iron-chelating agents].
Esposito L; Ferrara M; Ponte G
Pediatria (Napoli); 1981 Sep; 89(3):479-92. PubMed ID: 7346759
[No Abstract] [Full Text] [Related]
5. [Evaluation of iron overload in thalassemia].
Piga A; Davico S; Magliano M; Luzzatto L; Sandri A; Gabutti V
Pediatr Med Chir; 1986; 8(1):9-13. PubMed ID: 3725619
[TBL] [Abstract][Full Text] [Related]
6. Desferrioxamine induced urinary iron excretion in thalassemia.
Dubey AP; Kumar S; Choudhury P; Talukdar B; Puri RK
Indian Pediatr; 1993 Jun; 30(6):775-8. PubMed ID: 8132258
[TBL] [Abstract][Full Text] [Related]
7. [Thalassemia major: chelating therapy with deferoxamine].
Abreu de Miani MS; Sanchis de Herrlein MS; Peñalver JA
Medicina (B Aires); 1985; 45(3):231-4. PubMed ID: 3841934
[No Abstract] [Full Text] [Related]
8. Medical management of beta-thalassemia.
Lerner N
Prog Clin Biol Res; 1989; 309():13-22. PubMed ID: 2780747
[No Abstract] [Full Text] [Related]
9. Subcutaneous desferrioxamine: the effect of three years' treatment on liver, iron, serum ferritin, and comments on echocardiography.
Flynn DM; Hoffbrand AV; Politis D
Birth Defects Orig Artic Ser; 1982; 18(7):347-53. PubMed ID: 6819017
[No Abstract] [Full Text] [Related]
10. Iron overload in thalassemia: comparative analysis of magnetic resonance imaging, serum ferritin and iron content of the liver.
Mazza P; Giua R; De Marco S; Bonetti MG; Amurri B; Masi C; Lazzari G; Rizzo C; Cervellera M; Peluso A
Haematologica; 1995; 80(5):398-404. PubMed ID: 8566878
[TBL] [Abstract][Full Text] [Related]
11. Iron metabolism in thalassemia intermedia.
Fiorelli G; Fargion S; Piperno A; Battafarano N; Cappellini MD
Haematologica; 1990; 75 Suppl 5():89-95. PubMed ID: 2086386
[TBL] [Abstract][Full Text] [Related]
12. Serum ferritin underestimates liver iron concentration in transfusion independent thalassemia patients as compared to regularly transfused thalassemia and sickle cell patients.
Pakbaz Z; Fischer R; Fung E; Nielsen P; Harmatz P; Vichinsky E
Pediatr Blood Cancer; 2007 Sep; 49(3):329-32. PubMed ID: 17554789
[TBL] [Abstract][Full Text] [Related]
13. Serum ferritin concentrations in transfusion dependent beta-thalassaemia.
George E; Wong HB; George R; Ariffin WA
Singapore Med J; 1994 Feb; 35(1):62-4. PubMed ID: 8009283
[TBL] [Abstract][Full Text] [Related]
14. A controlled trial of long-term chelation therapy in homozygous beta-thalassemia.
Letsky EA
Birth Defects Orig Artic Ser; 1976; 12(8):31-41. PubMed ID: 1009233
[No Abstract] [Full Text] [Related]
15. Iron chelating therapy in thalassemia: current problems.
Russo G
Haematologica; 1990; 75 Suppl 5():84-8. PubMed ID: 2086385
[No Abstract] [Full Text] [Related]
16. Outcomes, utilization, and costs among thalassemia and sickle cell disease patients receiving deferoxamine therapy in the United States.
Delea TE; Hagiwara M; Thomas SK; Baladi JF; Phatak PD; Coates TD
Am J Hematol; 2008 Apr; 83(4):263-70. PubMed ID: 17924547
[TBL] [Abstract][Full Text] [Related]
17. Iron chelation in thalassemia: mechanism of desferrioxamine action.
Hershko C; Rachmilewitz EA
Isr J Med Sci; 1978 Nov; 14(11):1111-5. PubMed ID: 750535
[TBL] [Abstract][Full Text] [Related]
18. [Nuclear magnetic resonance and iron overload in thalassemia].
Schettini F; De Mattia D; Cavallo L; Sabato V; Santoro N; Del Vecchio GC; Martinelli G; Martinelli A; Di Bartolomeo P; Di Girolamo G
Minerva Pediatr; 1991 Dec; 43(12):777-81. PubMed ID: 1798402
[TBL] [Abstract][Full Text] [Related]
19. [Effect of two years of deferoxamine therapy on iron balance, ferritin, liver and heart in patients with thalassemia major].
Flückiger A; Imbach P; Pfenninger E; Stocker F; Töndury P; Wagner HP; Weber J; Zuppinger K
Helv Paediatr Acta; 1985 Sep; 40(4):293-304. PubMed ID: 4077563
[TBL] [Abstract][Full Text] [Related]
20. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients.
Shalitin S; Carmi D; Weintrob N; Phillip M; Miskin H; Kornreich L; Zilber R; Yaniv I; Tamary H
Eur J Haematol; 2005 Feb; 74(2):93-100. PubMed ID: 15654898
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
